Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2004

View Archived Issues

Leptin may regulate energy balance by posttranslational modulation of the melanocortin pathway

Antiparasitic drug effective against SARS in vitro

Array BioPharma and QLT collaborate in cancer therapeutics discovery

Caprion awarded NIAID grant for biodefense research

Acuity files IND for phase I trials of Cand5

Novel promising agent for inflammatory bowel disease and glomerulonephritis therapy

Baxter signs as contract manufacturer for Morphotek's MORAb-003

GB Therapeutics acquires license for Chiesi's NMDA antagonist

European orphan drug designation for TheraCIM hR3

A role for doxycycline in cardioprotection

Geranylgeranylacetone effective against coronary dysfunction in vivo

Mechanisms of melatonin cardioprotection

Pharmacia presents new CDK inhibitors

Novel factor Xa and/or factor VIIa inhibitors under study at Aventis

Teijin claims new vitamin D3 analogues for osteoporosis and other disorders

Ajinomoto presents new prodrugs of factor Xa inhibitors

New aminobenzophenone prodrugs and their use in skin inflammatory disorders

New immunosuppressants in early development at Sumitomo

Novel PPARdelta agonists and their use in diabetes, dyslipidemia, etc.

Encouraging topline data from phase II ramoplanin study

Zimycan meets endpoints in phase III study for Candida diaper dermatitis

BioDelivery Sciences to acquire Arius Pharmaceuticals

TheraQuest meets with U.S., U.K., Canadian authorities regarding TQ-1011

Evotec OAI and Seikagaku collaborate in inflammatory disease

Novartis exercises option to Vernalis' lead Hsp90 oncology program

Prous Science Award supports research in the field of microwave-assisted chemistry

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...